The healthcare group at BIS Analysis, lately, concluded an intensive webinar on ‘Liquid Biopsy: An Rising Frontier in Early Multicancer Detection’. The webinar was hosted by principal marketing consultant, Nitish Kumar, and senior analysis analyst, Riya Gupta. The visitor on this webinar was Mr. Azeet Narayan, principal scientist at Sema4.

The session was stuffed with trade insights in addition to deep advertising intelligence round liquid biopsy method and its affect on multicancer detection course of. Some very crucial questions have been raised in the course of the session by the attendees, which have been duly answered by the panel of audio system.

Right here’s an excerpt from the QnA that occurred in the course of the webinar:

a)    How do you see the marketplace for end-to-end options vs. modular method reminiscent of separate suppliers for kits and separate suppliers for evaluation software program?

In line with BIS Analysis evaluation, the liquid biopsy market will be divided in response to completely different choices into testing companies, kits, platform and different consumables. Out of those testing companies are anticipated to dominate the market with a 40-50% market share, adopted by platform with a 20-30% market share in 2021. Kits had a market share between 5-15% and Different consumables 15-25% in 2021.

b)    Why do you assume extracellular vesicles (EVs) will dominate the liquid biopsy market within the coming future, is it by way of medical facets or plain analysis facets?

Many of the EV primarily based merchandise in market presently are for analysis use solely. These merchandise nonetheless have been accredited for medical functions. So, the EV primarily based liquid biopsy market was estimated utilizing these product revenues.

c)    As you mentioned Azeet, there are a lot of sequencer and PCR errors whereas sequencing, which makes it laborious to tell apart true mutants from these errors. How do you be sure that is decreased?

We’ve got provide you with a way often known as clonal overlapping paired-end sequencing, by which we’re sequencing each strands of the DNA individually after which match the mutation overlaps. This fashion solely the true mutations are left and all of the instrument mutations will be eliminated.

d)    How do you count on the liquid biopsy methods to enter the worldwide market. Which areas are adopting the methods most rapidly?

As per BIS analysis evaluation, North America is predicted to dominate the worldwide liquid biopsy market in the course of the forecast interval 2022-2032. North America has a excessive adoption fee of liquid biopsy backed by a number of healthcare corporations working within the area. The U.S. has the best implementation of PCR, NGS, and different applied sciences within the globe. Then again, Asia-Pacific is predicted to witness the best compound annual development fee (CAGR) of 15-25% in the course of the forecast interval 2022-2032. The expansion within the Asia-Pacific market is predicted to be additional enhanced by different components reminiscent of a rise in healthcare consciousness, a gradual economic system resulting in the next deal with genomic analysis, and the widespread adoption of genome sequencing as the usual of care.

to be taught extra about this matter? Watch the whole video beneath: